Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Provided By PR Newswire

Last update: Apr 7, 2025

Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025